Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral TherapyThe ACTG (AIDS Clinical Trials Group) Study 5152s
Francesca J. Torriani, MD*,*,
Lauren Komarow, MS ,
Robert A. Parker, ScD ,
Bruno R. Cotter, MD, FACC*,
Judith S. Currier, MD ,
Michael P. Dubé, MD ,
Carl J. Fichtenbaum, MD||,
Mariana Gerschenson, PhD¶,
Carol K.C. Mitchell, PhD#,
Robert L. Murphy, MD**,
Kathleen Squires, MD ,
James H. Stein, MD, FACC# for the ACTG 5152s Study Team
* University of California–San Diego, San Diego, California
Harvard School of Public Health, Boston, Massachusetts
University of California–Los Angeles, Los Angeles, California
Indiana University School of Medicine, Indianapolis, Indiana
|| University of Cincinnati Medical Center, Cincinnati, Ohio
¶ University of Hawaii, Honolulu, Hawaii
# University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
** Northwestern University Feinberg School of Medicine, Chicago, Illinois
 University of Southern California, Los Angeles, California.

View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Changes in Brachial Artery Flow-Mediated Dilation From Baseline to Week 24
Thick bars = medians; box edges = 25th and 75th percentiles; error bars = 95% confidence intervals. EFV = efavirenz; FMD = flow-mediated dilation; LPV/r = lopinavir/ritonavir; NNRTI = non-nucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor. *p 0.005, #p = 0.015 within arm, compared with baseline (between groups, p = 0.828).
|
|
|